Table Of ContentAdvances in Experimental Medicine
and Biology
Volume 850
Editorial Board:
IRUN R. COHEN, The Weizmann Institute of Science, Rehovot, Israel
ABEL LAJTHA, N.S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA
JOHN D. LAMBRIS, University of Pennsylvania, Philadelphia, PA, USA
RODOLFO PAOLETTI, University of Milan, Milan, Italy
Advances in Experimental Medicine and Biology presents multidisciplinary and
dynamic findings in the broad fields of experimental medicine and biology. The
wide variety in topics it presents offers readers multiple perspectives on a variety
of disciplines including neuroscience, microbiology, immunology, biochemistry,
biomedical engineering and cancer research. Advances in Experimental Medicine
and Biology has been publishing exceptional works in the field for over 30 years
and is indexed in Medline, Scopus, EMBASE, BIOSIS, Biological Abstracts, CSA,
Biological Sciences and Living Resources (ASFA-1), and Biological Sciences. The
series also provides scientists with up to date information on emerging topics and
techniques. 2014 Impact Factor: 1.958
More information about this series at http://www.springer.com/series/5584
Stephen P. Schoenberger · Peter D. Katsikis ·
Bali Pulendran
Editors
Crossroads Between Innate
and Adaptive Immunity V
1 3
Editors
Stephen P. Schoenberger Bali Pulendran
Laboratory of Cellular Immunology Yerkes National Primate Research Center
La Jolla Institute for Allergy and Immun Emory University Emory Vaccine Center &
La Jolla Atlanta
USA Georgia
USA
Peter D. Katsikis
Department Microbiology & Immunology
Drexel University College of Medicine
Philadelphia
Pennsylvania
USA
ISSN 0065-2598 ISSN 2214-8019 (electronic)
Advances in Experimental Medicine and Biology
ISBN 978-3-319-15773-3 ISBN 978-3-319-15774-0 (eBook)
DOI 10.1007/978-3-319-15774-0
Library of Congress Control Number: 2015948173
Springer Cham Heidelberg New York Dordrecht London
© Springer International Publishing Switzerland 2015
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part
of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations,
recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or
information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar
methodology now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication
does not imply, even in the absence of a specific statement, that such names are exempt from the relevant
protective laws and regulations and therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and information in this book
are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the
editors give a warranty, express or implied, with respect to the material contained herein or for any errors
or omissions that may have been made.
Printed on acid-free paper
Springer International Publishing AG Switzerland is part of Springer Science+Business Media
(www.springer.com)
Contents
1 T ype III interferons (IFNs): Emerging Master Regulators
of Immunity .............................................................................................. 1
Ioanna E. Galani, Ourania Koltsida and Evangelos Andreakos
2 Stability of Regulatory T Cells Undermined or Endorsed by
Different Type-1 Cytokines ..................................................................... 17
Silvia Piconese and Vincenzo Barnaba
3 T he Role of Il-12 and Type I Interferon in Governing the
Magnitude of CD8 T Cell Responses ...................................................... 31
Gabriel R. Starbeck-Miller and John T. Harty
4 Functional Diversity of Human Dendritic Cells .................................... 43
Eynav Klechevsky
5 Selective Dependence of Kidney Dendritic Cells on
CX CR1—Implications for Glomerulonephritis Therapy ................... 55
3
Katharina Hochheiser and Christian Kurts
6 Mechanisms of Memory T Cell Activation and Effective
Immunity .................................................................................................. 73
Grégoire Lauvau and Saïdi M’Homa Soudja
7 Molecular Programming of Immunological Memory in
Natural Killer Cells .................................................................................. 81
Aimee M. Beaulieu, Sharline Madera and Joseph C. Sun
8 Induction of Immune Tolerance to Dietary Antigens ........................... 93
Kwang Soon Kim and Charles D. Surh
v
vi Contents
9 The Role of p110δ in the Development and Activation of B
Lymphocytes ............................................................................................. 119
Rebecca Newman and Martin Turner
10 I mmune Memory and Exhaustion: Clinically Relevant
Lessons from the LCMV Model ............................................................. 137
D. Zehn and E. J. Wherry
Index ................................................................................................................ 153
Contributors
Evangelos Andreakos Department of Immunology, Center for Translational and
Clinical Research, Biomedical Research Foundation, Academy of Athens, Athens,
Greece
Vincenzo Barnaba Dipartimento di Medicina Interna e Specialità Mediche,
Sapienza Università di Roma, Rome, Italy
Istituto Pasteur -Fondazione Cenci Bolognetti, Rome, Italy
Aimee M. Beaulieu Memorial Sloan Kettering Cancer Center, New York, NY,
USA
Ioanna E. Galani Department of Immunology, Center for Translational and
Clinical Research, Biomedical Research Foundation, Academy of Athens, Athens,
Greece
John T. Harty Interdisciplinary Graduate Program in Immunology, University of
Iowa, Iowa City, IA, USA
Department of Microbiology, University of Iowa, Iowa City, IA, USA
Katharina Hochheiser Institute of Experimental Immunology(IMMEI),
Rheinische Friedrich-Wilhelms University, Bonn, Germany
Kwang Soon Kim Academy of Immunology and Microbiology (AIM), Institute
for Basic Science (IBS), Pohang, Republic of Korea
Department of Integrative Biosciences and Biotechnology, Pohang University of
Science and Technology (POSTECH), Pohang, Republic of Korea
Eynav Klechevsky Washington University School of Medicine, St. Louis, USA
Ourania Koltsida Department of Immunology, Center for Translational and
Clinical Research, Biomedical Research Foundation, Academy of Athens, Athens,
Greece
Christian Kurts Institute of Experimental Immunology(IMMEI), Rheinische
Friedrich-Wilhelms University, Bonn, Germany
vii
viii Contributors
Grégoire Lauvau Department of Microbiology and Immunology, Albert Einstein
College of Medicine, Bronx, NY, USA
Sharline Madera Memorial Sloan Kettering Cancer Center, New York, NY, USA
Rebecca Newman Laboratory of Lymphocyte Signalling and Development, The
Babraham Institute, Babraham, UK
Silvia Piconese Dipartimento di Medicina Interna e Specialità Mediche, Sapienza
Università di Roma, Rome, Italy
Saïdi M’Homa Soudja Department of Microbiology and Immunology, Albert
Einstein College of Medicine, Bronx, NY, USA
Gabriel R. Starbeck-Miller Interdisciplinary Graduate Program in Immunology,
University of Iowa, Iowa City, IA, USA
Joseph C. Sun Memorial Sloan Kettering Cancer Center, New York, NY, USA
Charles D. Surh Academy of Immunology and Microbiology (AIM), Institute for
Basic Science (IBS), Pohang, Republic of Korea
Department of Integrative Biosciences and Biotechnology, Pohang University of
Science and Technology (POSTECH), Pohang, Republic of Korea
Division of Developmental Immunology, La Jolla institute for Allergy and
Immunology, La Jolla, CA, USA
Martin Turner Laboratory of Lymphocyte Signalling and Development, The
Babraham Institute, Babraham, UK
E. J. Wherry Department of Microbiology, Institute for Immunology, Philadelphia,
PA, USA
D. Zehn Division of Immunology and Allergy, Lausanne University Hospital,
Lausanne, Switzerland
Chapter 1
Type III interferons (IFNs): Emerging Master
Regulators of Immunity
Ioanna E. Galani, Ourania Koltsida and Evangelos Andreakos
Abstract Lambda interferons (IFN-λs), type III interferons or interleukins 28 and
29 are the latest addition to the class II cytokine family. They share low homology
with the interferon (IFN) and IL-10 cytokine families, yet they exhibit common and
unique activities, the full spectrum of which still remains incompletely understood.
Although initially described for their antiviral functions, it is now appreciated that
IFN-λs also mediate diverse antitumor and immune-modulatory effects, and are key
determinants of innate immunity at mucosal sites such as the gastrointestinal and
respiratory tracks. Here, we are reviewing the biological functions of IFN-λs, the
mechanisms controlling their expression, their downstream effects and their role
in the maintenance of homeostasis and disease. We are also exploring the potential
application of IFN-λs as novel therapeutics.
Keywords Lambda interferons (IFN-λs) · Type III interferons · Interleukin 28 ·
Interleukin 29 · Antiviral activity · Mucosal immunity
Type III IFNs or Lambda IFNs: A Unique Interferon
Family
Interferons (IFNs) were originally described over 50 years ago as anti-viral pro-
teins. However, they have since been shown to regulate multiple other biological
processes including cell proliferation and survival, inflammation and immunity.
They have also been implicated in many pathological situations including infec-
tions, cancer and autoimmunity. The diversity and functional organization of this
family became obvious in the 1980s with the cloning of the IFN-β gene and several
isoforms of IFN-α. This led to the realization that most of these molecules are part
of a single family, the type I IFN or IFN-α/β family, and signal through the same
heterodimeric receptor comprising the IFNαR1 and IFNαR2 chains. In humans,
E. Andreakos () · I. E. Galani · O. Koltsida
Department of Immunology, Center for Translational and Clinical Research, Biomedical
Research Foundation, Academy of Athens, Athens 11527, Greece
e-mail: [email protected]
© Springer International Publishing Switzerland 2015 1
S. P. Schoenberger et al. (eds.), Crossroads Between Innate and Adaptive Immunity V,
Advances in Experimental Medicine and Biology 850, DOI 10.1007/978-3-319-15774-0_1
